Related Experiment Video
Updated: Aug 7, 2025

Continuous Video Electroencephalogram during Hypoxia-Ischemia in Neonatal Mice
Published on: June 11, 2020
Early Discontinuation of Phenobarbital After Acute Symptomatic Neonatal Seizures in the Term Newborn
Melisa Carrasco1, Sonia Lomeli Bonifacio1, Gabrielle deVeber1
1Department of Neurology (MC), University of Wisconsin and University Hospital, Madison, WI; Department of Pediatrics (Neonatology) (SLB), Lucile Packard Children's Hospital and Stanford University, Stanford, CA; Department of Pediatrics (Neurology) (GdV), The Hospital for Sick Children, SickKids Research Institute (Child Health Evaluative Sciences) and University of Toronto, Toronto, Ontario, Canada; and Department of Pediatrics (Neurology) (VC), The Hospital for Sick Children, SickKids Research Institute (Neuroscience and Mental Health) and University of Toronto, Ontario, Canada.
Abstract:
Acute symptomatic seizures in the term newborn are often seen after perinatal brain injury. Common etiologies include hypoxic-ischemic encephalopathy, ischemic stroke, intracranial hemorrhage, metabolic derangements, and intracranial infections. Neonatal seizures are often treated with phenobarbital, which may cause sedation and may have significant long-term effects on brain development. Recent literature has suggested that phenobarbital may be safely discontinued in some patients before discharge from the neonatal intensive care unit. Optimizing a strategy for selective early phenobarbital discontinuation would be of great value. In this study, we present a unified framework for phenobarbital discontinuation after resolution of acute symptomatic seizures in the setting of brain injury of the newborn.
Related Concept Videos
Antiepileptic Drugs: Sodium Channel Blockers
Sodium channel blockers modulate ion channels, particularly voltage-gated sodium channels. They block only sodium ion movement.
Among the most commonly prescribed antiepileptic drugs are...
Sedatives and Hypnotics Drugs: Barbiturates
Antiepileptic Drugs: GABAergic Pathway Potentiators
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Potassium Channel Activators
Ezogabine has gained approval as an adjunctive treatment...
CNS Depressants: Barbiturates and Benzodiazepines

